Alnylam's R&D update includes 3 halts, Alzheimer's timeline and another NASH
Alnylam Pharmaceuticals touted its high probability of success in bringing assets from Phase I to Phase III — about 62% compared to an industry average of 5% to 10% — in an R&D update Thursday.
But, even the RNAi drug developer with five medicines now under its wings will come out with the scissors and scrap studies it finds lacking, as the Boston-area biotech outlined in an investor presentation. That includes cemdisiran for kidney disease IgA nephropathy, an early-stage drug for gout and lumasiran for recurrent renal stones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.